Steve Gillis
InvestorManaging Director at ARCH Venture Partners · Board director at hC Bioscience · Board director at Skylark Bio · Board director at Pheast Therapeutics
Seattle, Washington
Writes $50K – $150M checks · typically $25M
Find your path to Steve
98 people in our graph share verified history with Steve — schools, employers, funds. One of them is your warm intro.
About
Steve Gillis is an immunologist-turned-VC who founded Immunex and Corixa, helped develop Enbrel, and leverages roles at Takeda and early-stage biotech boards to bridge science and pharma operations.
Contact· self-published, not guessed
Likely email· guessed from name + firm domain, not firm-published
- s•••@archventure.comreveal100% confident
Invests in
AI & Machine LearningBiotechDeep TechHardwareHealthtechMedical Devices
Board director at hC Bioscience
Intro paths
In turn, Steve can intro founders to hC Bioscience's investors below.
hC Bioscience's investors · 4
Co-founders at hC Bioscience
Board director at Skylark Bio
Intro paths
In turn, Steve can intro founders to Skylark Bio's investors below.
Skylark Bio's investors · 1
Board director at Pheast Therapeutics
Intro paths
In turn, Steve can intro founders to Pheast Therapeutics's investors below.
Pheast Therapeutics's investors · 4
Co-founders at Pheast Therapeutics
Experience
- ARCH Venture PartnersManaging Director
Deals · 1
Skylark BioBoard seat
via ARCH Venture Partners · filed Apr 2024 · $40.9M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Investor
AllozyneBasking BiosciencesBE BiopharmaBitterroot BioCarrick TherapeuticsDispatch BioeGenesisFaraday PharmaceuticalsGenetix Biotherapeutics Inc.hC BioscienceHiberCellImmusanTLifordi ImmunotherapeuticsMozart TherapeuticsPheast TherapeuticsPronirasPulmatrixSonoTheraTFC TherapeuticsTheraclone SciencesVBI VaccinesVBI Vaccines (formerly SciVac Therapeutics)VentiRx PharmaceuticalsVilyaWalden Biosciences
Sources: SEC Form D filings · curated public sources.
Colleagues at ARCH Venture Partners
Network1
Investors connected to Steve in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Steve Gillis?
- Steve Gillis is an immunologist-turned-VC who founded Immunex and Corixa, helped develop Enbrel, and leverages roles at Takeda and early-stage biotech boards to bridge science and pharma operations.
- Where does Steve Gillis work?
- Steve Gillis is Managing Director at ARCH Venture Partners and Board director at hC Bioscience and Board director at Skylark Bio and Board director at Pheast Therapeutics.
- What does Steve Gillis invest in?
- Steve Gillis invests in AI & Machine Learning, Biotech, Deep Tech, Hardware, Healthtech, Medical Devices.
- What check size does Steve Gillis write?
- Steve Gillis typically writes checks of $50K – $150M.
- What boards does Steve Gillis sit on?
- Steve Gillis holds tracked board seats at Basking Biosciences, Skylark Bio.
- What companies has Steve Gillis invested in?
- Investments tracked here include Allozyne, Basking Biosciences, BE Biopharma, Bitterroot Bio, Carrick Therapeutics, Dispatch Bio, eGenesis, Faraday Pharmaceuticals, Genetix Biotherapeutics Inc., hC Bioscience, HiberCell, ImmusanT, and 13 more.
Shared employers
Also worked at ARCH Venture Partners38
+ 32 more